Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1990 Feb;69(2):209–214.

Interleukin-2-dependent control of disease development in spontaneously diabetic BB rats.

J Zielasek 1, V Burkart 1, P Naylor 1, A Goldstein 1, U Kiesel 1, H Kolb 1
PMCID: PMC1385591  PMID: 2307481

Abstract

Long-term treatment with recombinant interleukin-2 (IL-2) of diabetes-prone BB rats had contrasting effects in two different BB rat sublines. Diabetes development was enhanced in the subline with a low intrinsic diabetes risk and suppressed in the subline with a high diabetes risk. IL-2 treatment started between 35 and 42 days of age and lasted for 3 months. In subline 1, diabetes incidence increased from 23% to 53% (P less than 0.01), in subline 2 it decreased from 73% to 32% (P less than 0.01). The two sublines differed in serum levels of factors controlling IL-2 synthesis and activity. Mean IL-2 inhibitory activity was higher in subline 2 (between 140% and 290% of levels in subline 1, P less than 0.01). Conversely, mean concentrations of thymosin alpha 1 and beta 4 were higher in subline 1 (between 140% and 200% of levels in subline 2, P less than 0.01). Thus the two sublines differ in their response to exogenous IL-2 and also in serum levels of mediators affecting availability of IL-2. We conclude that an internal network of hormonal factors, including IL-2, contributes to the control of diabetes development in the BB rat.

Full text

PDF
209

Images in this article

211Figure 2
on p.211

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brocke S., Takacs L., Gerdes J., Osawa H., Diamantstein T. The ontogeny of the interleukin 2 receptor expression and of the interleukin 2 responsiveness in the rat thymus. Immunobiology. 1987 May;174(3):266–273. doi: 10.1016/S0171-2985(87)80002-5. [DOI] [PubMed] [Google Scholar]
  2. Burstein D., Handler E. S., Schindler J., Seals J., Mordes J. P., Rossini A. A. Effect of interleukin-2 on diabetes in the BB/Wor rat. Diabetes Res. 1987 Aug;5(4):163–167. [PubMed] [Google Scholar]
  3. Djeu J. Y., Kasahara T., Balow J. E., Tsokos G. C. Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders. Clin Exp Immunol. 1986 Aug;65(2):279–285. [PMC free article] [PubMed] [Google Scholar]
  4. Duclos H., Maillot M. C., Galanaud P. Interleukin induction of non-specific suppressor cells. Ann Inst Pasteur Immunol. 1986 Jan-Feb;137C(1):3–10. doi: 10.1016/s0771-050x(86)80001-8. [DOI] [PubMed] [Google Scholar]
  5. Dyrberg T., Nakhooda A. F., Baekkeskov S., Lernmark A., Poussier P., Marliss E. B. Islet cell surface antibodies and lymphocyte antibodies in the spontaneously diabetic BB Wistar rat. Diabetes. 1982 Mar;31(3):278–281. doi: 10.2337/diab.31.3.278. [DOI] [PubMed] [Google Scholar]
  6. Elder M. E., Maclaren N. K. Identification of profound peripheral T lymphocyte immunodeficiencies in the spontaneously diabetic BB rat. J Immunol. 1983 Apr;130(4):1723–1731. [PubMed] [Google Scholar]
  7. Frasca D., Adorini L., Mancini C., Doria G. Reconstitution of T cell functions in aging mice by thymosin alpha 1. Immunopharmacology. 1986 Jun;11(3):155–163. doi: 10.1016/0162-3109(86)90017-2. [DOI] [PubMed] [Google Scholar]
  8. Fujiwara H., Toossi Z., Ohnishi K., Edmonds K., Ellner J. J. Spontaneous production of a suppressor factor by a human macrophage-like cell line U937. II. Suppression of antigen- and mitogen-induced blastogenesis, IL 2 production and IL 2 receptor expression in T lymphocytes. J Immunol. 1987 Jan 1;138(1):197–203. [PubMed] [Google Scholar]
  9. Fukushima T., Kobayashi K., Kasama T., Kasahara K., Tabata M., Sekine F., Negishi M., Ide H., Takahashi T. Inhibition of interleukin 2 by serum in healthy individuals and in patients with autoimmune disease. Int Arch Allergy Appl Immunol. 1987;84(2):135–141. doi: 10.1159/000234412. [DOI] [PubMed] [Google Scholar]
  10. Gearing A. J., Wadhwa M., Perris A. D. In vivo administration of interleukin 2 stimulates mitosis in thymus and bone marrow. Eur J Immunol. 1986 Sep;16(9):1171–1174. doi: 10.1002/eji.1830160923. [DOI] [PubMed] [Google Scholar]
  11. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  12. Giordano C., Galluzzo A., Marco A., Pantò F., Amato M. P., Caruso C., Bompiani G. D. Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients. Diabetes Res. 1988 Jul;8(3):135–138. [PubMed] [Google Scholar]
  13. Giordano C., Pantò F., Caruso C., Modica M. A., Zambito A. M., Sapienza N., Amato M. P., Galluzzo A. Interleukin 2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients. Diabetes. 1989 Mar;38(3):310–315. doi: 10.2337/diab.38.3.310. [DOI] [PubMed] [Google Scholar]
  14. Hahn H. J., Lucke S., Klöting I., Volk H. D., Baehr R. V., Diamantstein T. Curing BB rats of freshly manifested diabetes by short-term treatment with a combination of a monoclonal anti-interleukin 2 receptor antibody and a subtherapeutic dose of cyclosporin A. Eur J Immunol. 1987 Jul;17(7):1075–1078. doi: 10.1002/eji.1830170728. [DOI] [PubMed] [Google Scholar]
  15. Hardt C., Röllinghoff M., Pfizenmaier K., Mosmann H., Wagner H. Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo. J Exp Med. 1981 Aug 1;154(2):262–274. doi: 10.1084/jem.154.2.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Honda M., Chan C., Shevach E. M. Characterization and partial purification of a specific interleukin 2 inhibitor. J Immunol. 1985 Sep;135(3):1834–1839. [PubMed] [Google Scholar]
  17. Jackson R., Rassi N., Crump T., Haynes B., Eisenbarth G. S. The BB diabetic rat. Profound T-cell lymphocytopenia. Diabetes. 1981 Oct;30(10):887–889. doi: 10.2337/diab.30.10.887. [DOI] [PubMed] [Google Scholar]
  18. Kaye W. A., Adri M. N., Soeldner J. S., Rabinowe S. L., Kaldany A., Kahn C. R., Bistrian B., Srikanta S., Ganda O. P., Eisenbarth G. S. Acquired defect in interleukin-2 production in patients with type I diabetes mellitus. N Engl J Med. 1986 Oct 9;315(15):920–924. doi: 10.1056/NEJM198610093151502. [DOI] [PubMed] [Google Scholar]
  19. Kolb H. Mouse models of insulin dependent diabetes: low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes Metab Rev. 1987 Jul;3(3):751–778. doi: 10.1002/dmr.5610030308. [DOI] [PubMed] [Google Scholar]
  20. Kolb H., Zielasek J., Treichel U., Freytag G., Wrann M., Kiesel U. Recombinant interleukin 2 enhances spontaneous insulin-dependent diabetes in BB rats. Eur J Immunol. 1986 Feb;16(2):209–212. doi: 10.1002/eji.1830160218. [DOI] [PubMed] [Google Scholar]
  21. Kramer M., Koszinowski U. T cell-specific suppressor factor(s) with regulatory influence on interleukin 2 production and function. J Immunol. 1982 Feb;128(2):784–790. [PubMed] [Google Scholar]
  22. Kroemer G., Klocker H., Faessler R., Sachsenmaier W., Wick G. Decreased level of thymidine in the serum of obese strain (OS) chickens with spontaneous autoimmune thyroiditis. Immunol Invest. 1988 May;17(3):243–256. doi: 10.3109/08820138809052964. [DOI] [PubMed] [Google Scholar]
  23. Kryspin-Sørensen I., Dyrberg T., Kastern W. Genetic heterogeneity in the major histocompatibility complex of various BB rat sublines. Diabetologia. 1986 May;29(5):307–312. doi: 10.1007/BF00452068. [DOI] [PubMed] [Google Scholar]
  24. Krömer G., Schauenstein K., Neu N., Stricker K., Wick G. In vitro T cell hyperreactivity in Obese strain (OS) chickens is due to a defect in nonspecific suppressor mechanism(s). J Immunol. 1985 Oct;135(4):2458–2463. [PubMed] [Google Scholar]
  25. Kucharz E. J., Goodwin J. S. Serum inhibitors of interleukin-2. Life Sci. 1988;42(16):1485–1491. doi: 10.1016/0024-3205(88)90004-5. [DOI] [PubMed] [Google Scholar]
  26. Lelchuk R., Playfair J. H. Serum IL-2 inhibitor in mice. I. Increase during infection. Immunology. 1985 Sep;56(1):113–118. [PMC free article] [PubMed] [Google Scholar]
  27. Lotze M. T., Frana L. W., Sharrow S. O., Robb R. J., Rosenberg S. A. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol. 1985 Jan;134(1):157–166. [PubMed] [Google Scholar]
  28. Maki T., Satomi S., Gotoh M., Monaco A. P. Contra-IL 2; a suppressor lymphokine that inhibits IL 2 activity. J Immunol. 1986 May 1;136(9):3298–3303. [PubMed] [Google Scholar]
  29. Male D., Lelchuk R., Curry S., Pryce G., Playfair J. H. Serum IL-2 inhibitor in mice. II. Molecular characteristics. Immunology. 1985 Sep;56(1):119–125. [PMC free article] [PubMed] [Google Scholar]
  30. Malkovsky M., Asherson G. L., Stockinger B., Watkins M. C. Nonspecific inhibitor released by T acceptor cells reduces the production of interleukin-2. Nature. 1982 Dec 16;300(5893):652–655. doi: 10.1038/300652a0. [DOI] [PubMed] [Google Scholar]
  31. Marliss E. B., Nakhooda A. F., Poussier P., Sima A. A. The diabetic syndrome of the 'BB' Wistar rat: possible relevance to type 1 (insulin-dependent) diabetes in man. Diabetologia. 1982 Apr;22(4):225–232. doi: 10.1007/BF00281296. [DOI] [PubMed] [Google Scholar]
  32. McClure J. E., Lameris N., Wara D. W., Goldstein A. L. Immunochemical studies on thymosin: radioimmunoassay of thymosin alpha 1. J Immunol. 1982 Jan;128(1):368–375. [PubMed] [Google Scholar]
  33. Mordes J. P., Desemone J., Rossini A. A. The BB rat. Diabetes Metab Rev. 1987 Jul;3(3):725–750. doi: 10.1002/dmr.5610030307. [DOI] [PubMed] [Google Scholar]
  34. Naylor P. H., Friedman-Kien A., Hersh E., Erdos M., Goldstein A. L. Thymosin alpha 1 and thymosin beta 4 in serum: comparison of normal, cord, homosexual and AIDS serum. Int J Immunopharmacol. 1986;8(7):667–676. doi: 10.1016/0192-0561(86)90001-9. [DOI] [PubMed] [Google Scholar]
  35. Naylor P. H., Goldstein A. L. Thymosin modulates immune and endocrine events. Prog Clin Biol Res. 1988;256:489–502. [PubMed] [Google Scholar]
  36. Pontesilli O., Chase H. P., Carotenuto P., Herberger M. J., Hayward A. R. T-lymphocyte subpopulations in insulin-dependent (type I) diabetes mellitus. Clin Exp Immunol. 1986 Jan;63(1):68–72. [PMC free article] [PubMed] [Google Scholar]
  37. Prud'homme G. J., Fuks A., Colle E., Seemayer T. A., Guttmann R. D. Immune dysfunction in diabetes-prone BB rats. Interleukin 2 production and other mitogen-induced responses are suppressed by activated macrophages. J Exp Med. 1984 Feb 1;159(2):463–478. doi: 10.1084/jem.159.2.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Pukel C., Baquerizo H., Rabinovitch A. Interleukin 2 activates BB/W diabetic rat lymphoid cells cytotoxic to islet cells. Diabetes. 1987 Nov;36(11):1217–1222. doi: 10.2337/diab.36.11.1217. [DOI] [PubMed] [Google Scholar]
  39. Reem G. H., Yeh N. H., Urdal D. L., Kilian P. L., Farrar J. J. Induction and upregulation by interleukin 2 of high-affinity interleukin 2 receptors on thymocytes and T cells. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8663–8666. doi: 10.1073/pnas.82.24.8663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Serrate S. A., Schulof R. S., Leondaridis L., Goldstein A. L., Sztein M. B. Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J Immunol. 1987 Oct 1;139(7):2338–2343. [PubMed] [Google Scholar]
  41. Signore A., Parman A., Pozzilli P., Andreani D., Beverley P. C. Detection of activated lymphocytes in endocrine pancreas of BB/W rats by injection of 123I-interleukin-2: an early sign of type 1 diabetes. Lancet. 1987 Sep 5;2(8558):537–540. doi: 10.1016/s0140-6736(87)92925-4. [DOI] [PubMed] [Google Scholar]
  42. Skotnicki A. B., Zatz M., Sztein M. B., Goldstein A. L., Schulof R. S. Effect of thymic hormones on interleukin 2 synthesis by lymphocytes from HIV-positive pre-AIDS subjects. Immunol Invest. 1988 Apr;17(2):159–164. doi: 10.3109/08820138809055727. [DOI] [PubMed] [Google Scholar]
  43. Sztein M. B., Serrate S. A., Goldstein A. L. Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci U S A. 1986 Aug;83(16):6107–6111. doi: 10.1073/pnas.83.16.6107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Tomazic V., Suter C. M., Chretien P. B. Experimental autoimmune thyroiditis: modulation of the disease level in high and low responder mice by thymosin. Clin Exp Immunol. 1984 Oct;58(1):83–89. [PMC free article] [PubMed] [Google Scholar]
  45. Volk H. D., Diamantstein T. IL-2 normalizes defective suppressor T cell function of patients with systemic lupus erythematosus in vitro. Clin Exp Immunol. 1986 Dec;66(3):525–531. [PMC free article] [PubMed] [Google Scholar]
  46. Wada S., Naylor P. H., Naylor C. W., Goldstein A. L. Improved ELISA to measure thymosin alpha 1: comparison of whole and absorbed antisera. Int J Immunopharmacol. 1988;10(7):795–801. doi: 10.1016/0192-0561(88)90002-1. [DOI] [PubMed] [Google Scholar]
  47. Winter W. E., Robbins V., Elder M., Barrett D., Martin N., Maclaren N. K. Thymosin and the spontaneously diabetic BB rat. Autoimmunity. 1988;1(2):115–123. doi: 10.3109/08916938809001924. [DOI] [PubMed] [Google Scholar]
  48. Zatz M. M., Goldstein A. L. Mechanism of action of thymosin. I. Thymosin fraction 5 increases lymphokine production by mature murine T cells responding in a mixed lymphocyte reaction. J Immunol. 1985 Feb;134(2):1032–1038. [PubMed] [Google Scholar]
  49. Zatz M. M., Oliver J., Samuels C., Skotnicki A. B., Sztein M. B., Goldstein A. L. Thymosin increases production of T-cell growth factor by normal human peripheral blood lymphocytes. Proc Natl Acad Sci U S A. 1984 May;81(9):2882–2885. doi: 10.1073/pnas.81.9.2882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Zier K. S., Leo M. M., Spielman R. S., Baker L. Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes. 1984 Jun;33(6):552–555. doi: 10.2337/diab.33.6.552. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES